News

Engrail Therapeutics Raises $32 Million in Series A Financing to develop neuroscience therapeutics

BY      |     June 18, 2020

Founded in 2019, Engrail Therapeutics, a biopharmaceutical company focused on the acquisition, development and commercialization of patient-centric neuroscience therapeutics, has raised $32 Million in Series A Financing to develop neuroscience therapeutics.

Engrail’s portfolio is led by a sub-type selective GABA A modulator, ENX-101, and the company plans to use the funding to support its clinical development.

Read the press release here.

Read more about Engrail Therapeutics here.



Image by Gerd Altmann from Pixabay.


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.